Barclays PLC Buys 58,897 Shares of ASP Isotopes Inc. (NASDAQ:ASPI)

Barclays PLC increased its stake in shares of ASP Isotopes Inc. (NASDAQ:ASPI) by 438.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 72,330 shares of the company’s stock after buying an additional 58,897 shares during the quarter. Barclays PLC owned 0.10% of ASP Isotopes worth $201,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. Jane Street Group LLC grew its stake in ASP Isotopes by 31.7% in the 3rd quarter. Jane Street Group LLC now owns 145,969 shares of the company’s stock valued at $406,000 after purchasing an additional 35,166 shares during the period. State Street Corp grew its stake in ASP Isotopes by 12.8% in the 3rd quarter. State Street Corp now owns 853,695 shares of the company’s stock valued at $2,373,000 after purchasing an additional 96,604 shares during the period. Philadelphia Financial Management of San Francisco LLC grew its stake in ASP Isotopes by 158.3% in the 3rd quarter. Philadelphia Financial Management of San Francisco LLC now owns 991,863 shares of the company’s stock valued at $2,757,000 after purchasing an additional 607,893 shares during the period. Verition Fund Management LLC bought a new position in ASP Isotopes in the 3rd quarter valued at $101,000. Finally, Walleye Capital LLC bought a new position in ASP Isotopes in the 3rd quarter valued at $536,000. Institutional investors own 16.80% of the company’s stock.

ASP Isotopes Stock Down 6.3 %

Shares of NASDAQ ASPI opened at $5.03 on Tuesday. ASP Isotopes Inc. has a one year low of $1.72 and a one year high of $9.33. The company has a debt-to-equity ratio of 0.80, a current ratio of 7.55 and a quick ratio of 7.54. The business’s fifty day moving average price is $5.93 and its 200-day moving average price is $3.97. The stock has a market capitalization of $359.09 million, a PE ratio of -8.25 and a beta of 3.48.

Wall Street Analysts Forecast Growth

ASPI has been the subject of a number of recent analyst reports. Canaccord Genuity Group initiated coverage on ASP Isotopes in a research note on Friday, October 4th. They issued a “buy” rating and a $4.50 price objective for the company. Canaccord Genuity Group restated a “buy” rating and issued a $4.50 price objective on shares of ASP Isotopes in a research note on Friday, October 18th.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.